China Biopharma Company Profile

21:38 EDT 23rd September 2018 | BioPortfolio

China Biopharma Inc. (Stock Symbol: CBPC.OB) is a fast growing provider of human vaccine products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines against influenza (flu), epidemic hemorrhagic fever (HF), and Japanese Encephalitis (JE). With its investment and ownership of local Chinese bio-pharmaceutical companies, the Company plans to build a leading bio-pharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and experienced management teams. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, the Company expects to see steady business growth in the near future.


31 Airpark Road
United States of America


Phone: 609-651-8588
Fax: 609-228-4301

News Articles [3480 Associated News Articles listed on BioPortfolio]

Loncar Launches China BioPharma ETF on NASDAQ Exchange

Loncar launched its China BioPharma ETF, a fund that gives international investors access to a diversified portfolio of China-based innovative biopharmas. The exchange-traded-fund currently holds 28 c...

Loncar Investment Starts China Biopharma Stock Index

Loncar Investments has launched its Loncar China Biopharma Index (LCHINA), an index comprised of 32 China publicly traded biotech companies. The index, which is re-priced once a day, includes innovati...

Can-Fite BioPharma: Multi-Millionen-Deal in China

Mit Can-Fite BioPharma (ISIN: US13471N1028) gelingt einem unserer No-Brainer-Kandidaten ein saftiger Lizenzdeal in China. Das Abkommen umfasst die zwei fortgeschrittensten Produktkandidaten des Unt...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vacc...

Is the biopharma industry safe from the US-China trade war?

On 3 April, the US Trade Representative’s (USTR) office announced its intention to add a 25% tariff on around $50bn...Read More... The post Is the biopharma industry safe from the US-China trade war...

China’s Emergence Into the Global Pharma Industry

Recently big pharma have been taking advantage of the financial and industrial environment in China. In this interview Fintan Walton and Dr. Bill Guo, founder and Chairman of Venturepharm, take a look...

I-Mab Biopharma Files China IND for I-O Multiple Myeloma Treatment

Shanghai's I-Mab BioPharma has submitted an IND in China for approval to conduct clinical trials of its immuno-oncology multiple myeloma treatment. TJ202/MOR202 is a mAb that is directed against CD38,...

Ascletis, a Pre-Revenue China Biopharma, Files for Hong Kong IPO

Ascletis Pharma of Hangzhou has the honor of being the first pre-revenue China biopharma to file for a Hong Kong IPO. Previously, a company had to show two years of profitability before the exchange w...

PubMed Articles [1082 Associated PubMed Articles listed on BioPortfolio]

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the inte...

Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.

Hepatitis B virus (HBV) infection is a major public health threat in China for China has a hepatitis B prevalence of more than one million people in 2017 year. Disease incidence prediction may help he...

HIV epidemics in Shenzhen and Chongqing, China.

Men who have sex with men (MSM) and heterosexuals are the populations with the fastest growing HIV infection rates in China. We characterize the epidemic growth and age patterns between these two rout...

High relative risk of all-cause mortality attributed to smoking in China: Guangzhou Biobank Cohort Study.

Prediction of disease burden in China arising from smoking based on earlier cohorts in the West and China could not reflect the disease burden at the current stage accurately. No cohort studies in Chi...

Emission Characteristics of Particulate Matter from Diesel Buses Meeting Different China Emission Standards Fueled with Biodiesel.

Based on heavy chassis dynamometer, an experimental study was conducted in diesel buses compliant with China Ⅲ,Ⅳ,Ⅴ emissions standards respectively, fueled with three different blends of petrole...

Clinical Trials [863 Associated Clinical Trials listed on BioPortfolio]

SYNERGY China: Assess SYNERGY Stent in China

Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.

Trevo® Retriever Registry (China)

Trevo® Retriever Registry (China) is to assess real world performance of the SDA cleared Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus in pat...

China PEACE Millions Persons Project

China PEACE Millions Persons Project is a national screening project for cardiovascular disease in China. This Project was approved by National Health and Family Planning Commission (NHFPC...

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

Study of China Heart Failure Registry to Investigate Characteristics of Patients in China

The purpose of this study is to assess clinical characteristics, treatment, and outcome of patients hospitalized with heart failure in China and compared those with other registries

Companies [662 Associated Companies listed on BioPortfolio]

China Biopharma

China Biopharma Inc. (Stock Symbol: CBPC.OB) is a fast growing provider of human vaccine products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority ...

SAFE-BioPharma Association

SAFE-BioPharma Association ( is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [] provides global, high-assurance identity...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

More Information about "China Biopharma" on BioPortfolio

We have published hundreds of China Biopharma news stories on BioPortfolio along with dozens of China Biopharma Clinical Trials and PubMed Articles about China Biopharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of China Biopharma Companies in our database. You can also find out about relevant China Biopharma Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record